The division of myelodysplastic syndromes (MDS) into low-risk and high-risk categories guides prognosis and treatment, with patients who have lower-risk disease typically receivin ...
The Novel Allosteric NEK7 Inhibitor Ofirnoflast (HT-6184) Demonstrates Robust and Sustained Hematologic Response in Subjects with IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndrome ...
ECOG performance status, IPSS risk scores, bone marrow blast percentage, TP53 mutations, and cytogenetic abnormalities independently predicted prognosis. Complete remission significantly improved ...
Which of the statements below about the prognosis of myelodysplastic syndromes (MDS) are correct? Select one of the options for each question, then submit your answers to see how well you scored and ...
Purpose: Myelodysplastic syndromes (MDS) are a group of hematological disorders that remain relatively under-explored, which are characterized by inconspicuous early symptoms and generally poor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback